Ordena

Cercar

09/02/2022 Interaction between rs10830962 polymorphism in MTNR1B and lifestyle intervention on maternal and neonatal outcomes: secondary analyses of the DALI lifestyle randomized controlled trial
van Poppel, MNM, Corcoy, R, Hill, D, Simmons, D, Mendizabal, L, Zulueta, M, Simon, L, Desoye, G, Perez, JMA, Kautzky-Willer, A, Harreiter, J, Damm, P, Mathiesen, E, Jensen, DM, Andersen, LLT, Dunne, F, Lapolla, A, Dalfra, MG, Bertolotto, A, van Poppel, M, Jelsma, JGM, Snoek, FJ, Galjaard, S, Wender-Ozegowska, E, Zawiejska, A, Devlieger, R, DALI Core Investigator Grp. Interaction between rs10830962 polymorphism in MTNR1B and lifestyle intervention on maternal and neonatal outcomes: secondary analyses of the DALI lifestyle randomized controlled trial. AMERICAN JOURNAL OF CLINICAL NUTRITION. 2022; 115(2)DOI:10.1093/ajcn/nqab347. PMID:34669935. IF:7.100(Q1/2D).
08/02/2022 Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
Hughes, DA, Aguiar, P, Lidove, O, Nicholls, K, Nowak, A, Thomas, M, Torra, R, Vujkovac, B, West, ML, Feriozzi, S. Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?. Orphanet Journal of Rare Diseases. 2022; 17(1)DOI:10.1186/s13023-022-02181-4. PMID:35135579. IF:3.700(Q2/4D).
08/02/2022 Non-invasive oxygenation support in acutely hypoxemic COVID-19 patients admitted to the ICU: a multicenter observational retrospective study
Wendel-Garcia, PD, Mas, A, Gonzalez-Isern, C, Ferrer, R, Manez, R, Masclans, JR, Sandoval, E, Vera, P, Trenado, J, Fernandez, R, Sirvent, JM, Martinez, M, Ibarz, M, Garro, P, Lopera, JL, Bodi, M, Yebenes-Reyes, JC, Triginer, C, Vallverdu, I, Baro, A, Bodi, F, Saludes, P, Valencia, M, Roche-Campo, F, Huerta, A, Cambra, FJ, Barbera, C, Echevarria, J, Penuelas, O, Mancebo, J, UCIsCAT Study Grp. Non-invasive oxygenation support in acutely hypoxemic COVID-19 patients admitted to the ICU: a multicenter observational retrospective study. CRITICAL CARE. 2022; 26(1)DOI:10.1186/s13054-022-03905-5. PMID:35135588. IF:15.100(Q1/2D).
08/02/2022 Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
Pinana, JL, Garcia-Sanz, R, Martino, R, Garcia-Rao, M, Martin-Martin, GA, Risco-Galvez, I, Tormo, M, Martinez-Barranco, P, Marcos-Corrales, S, Calabuig, M, Conesa, V, Teruel, A, Ruiz-Perez, S, Solano, C, Navarro, D, Cedillo, A, Sureda, A. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021006326. PMID:34905620. IF:7.500(Q1/2D).